Spots Global Cancer Trial Database for stage iv mantle cell lymphoma

Every month we try and update this database with for stage iv mantle cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00019708	Extranodal Marg... Nodal Marginal ... Non-Hodgkin Lym... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu...	tanespimycin	19 Years -	National Cancer Institute (NCI)
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma	NCT00070447	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... yttrium Y 90 ib...	18 Years -	National Cancer Institute (NCI)
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT01527149	Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle...	Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul...	18 Years - 70 Years	Roswell Park Cancer Institute
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease	NCT00176475	Leukemia Lymphoma Multiple Myelom...	rituximab therapeutic all...	18 Years -	Rutgers, The State University of New Jersey
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma	NCT02652910	Recurrent Adult... Recurrent Folli... Recurrent Mantl... Stage III Adult... Stage III Folli... Stage III Mantl... Stage IV Adult ... Stage IV Follic... Stage IV Mantle...	CD19.CAR-T cell...	18 Years - 70 Years	Xinqiao Hospital of Chongqing
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma	NCT00003280	Lymphoma	rituximab	18 Years - 120 Years	Swiss Group for Clinical Cancer Research
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	NCT00980395	Lymphoma Mantle Cell Lym... Indolent Lympho... SLL	rituximab bortezomib cladribine	18 Years -	University of Arizona
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202	NCT00896662	Lymphoma Solid Tumor	immunologic tec... laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	NCT00516412	Lymphoma	everolimus molecular respo...	18 Years -	Swiss Group for Clinical Cancer Research
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy	NCT00727207	Lymphoma	everolimus	40 Years -	Technical University of Munich
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma	NCT00278161	Leukemia Lymphoma	Pegfilgrastim Rituximab Cyclophosphamid...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma	NCT00020943	Lymphoma	filgrastim rituximab carmustine cyclophosphamid... cytarabine doxorubicin hyd... etoposide leucovorin calc... methotrexate prednisone vincristine sul... peripheral bloo...	18 Years - 69 Years	Alliance for Clinical Trials in Oncology
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00082823	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma	NCT00003356	Lymphoma	aldesleukin rituximab	18 Years - 75 Years	University of Rochester
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)	NCT00005626	Leukemia Lymphoma	Irinotecan	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003397	Lymphoma	filgrastim rituximab sargramostim carmustine cisplatin cyclophosphamid... dexamethasone etoposide gemcitabine hyd... melphalan paclitaxel bone marrow abl... peripheral bloo...	18 Years - 75 Years	University of Maryland, Baltimore
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer	NCT00248430	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom...	aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo...	18 Years - 69 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma	NCT00003541	Lymphoma	filgrastim CHOP regimen carboplatin cyclophosphamid... doxorubicin hyd... etoposide ifosfamide prednisone vincristine sul... peripheral bloo... radiation thera...	18 Years -	Memorial Sloan Kettering Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma	NCT00740415	Lymphoma	rituximab bortezomib dexamethasone Bendamustine	65 Years - 80 Years	French Innovative Leukemia Organisation
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT01045928	Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac...	lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom...	18 Years -	Case Comprehensive Cancer Center
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	NCT00010192	B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ...	rituximab aldesleukin laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma	NCT02242097	Contiguous Stag... Noncontiguous S... Stage I Mantle ... Stage III Mantl... Stage IV Mantle...	ibrutinib laboratory biom...	18 Years -	Northwestern University
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
PS-341 in Treating Patients With Advanced Cancer	NCT00006362	Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu...	bortezomib	18 Years -	Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma	NCT00006252	Leukemia Lymphoma	fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt...	- 69 Years	Alliance for Clinical Trials in Oncology
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer	NCT00782379	Leukemia Lymphoma Myelodysplastic...	busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo...	18 Years - 60 Years	Northside Hospital, Inc.
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00110006	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose...	18 Years -	Case Comprehensive Cancer Center
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	NCT00980395	Lymphoma Mantle Cell Lym... Indolent Lympho... SLL	rituximab bortezomib cladribine	18 Years -	University of Arizona
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma	NCT00101101	Lymphoma	Cyclophosphamid... Doxorubicin Vincristine Prednisone Dexamethasone Autologous Tumo... IL-2	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT00376961	Lymphoma	rituximab bortezomib cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	18 Years - 120 Years	SWOG Cancer Research Network
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	NCT00275080	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Secondary Acute... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Untreated Adult... Untreated Adult...	vorinostat decitabine	18 Years -	National Cancer Institute (NCI)
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma	NCT02242097	Contiguous Stag... Noncontiguous S... Stage I Mantle ... Stage III Mantl... Stage IV Mantle...	ibrutinib laboratory biom...	18 Years -	Northwestern University
Tipifarnib in Treating Patients With Advanced Hematologic Cancer	NCT00005967	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	tipifarnib	18 Years -	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	NCT00387959	Leukemia Lymphoma	filgrastim rituximab cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... umbilical cord ... total-body irra...	18 Years - 70 Years	Memorial Sloan Kettering Cancer Center
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia	NCT00004084	Leukemia Lymphoma	indium In 111 L... yttrium Y 90 ep...	18 Years -	Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT01527149	Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle...	Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul...	18 Years - 70 Years	Roswell Park Cancer Institute
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma	NCT00003280	Lymphoma	rituximab	18 Years - 120 Years	Swiss Group for Clinical Cancer Research
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma	NCT00018954	Leukemia Lymphoma	asparaginase cyclophosphamid... cytarabine daunorubicin hy... doxorubicin hyd... etoposide ifosfamide mercaptopurine methotrexate prednisone vincristine sul... conventional su... radiation thera...	-	National Institutes of Health Clinical Center (CC)
Bortezomib in Treating Patients With Mantle Cell Lymphoma	NCT00030875	Lymphoma	bortezomib	18 Years - 120 Years	Canadian Cancer Trials Group
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma	NCT00020943	Lymphoma	filgrastim rituximab carmustine cyclophosphamid... cytarabine doxorubicin hyd... etoposide leucovorin calc... methotrexate prednisone vincristine sul... peripheral bloo...	18 Years - 69 Years	Alliance for Clinical Trials in Oncology
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma	NCT00006747	Graft Versus Ho... Lymphoma	carmustine melphalan etoposide cytarabine tacrolimus methotrexate sargramostim transplant	- 59 Years	Alliance for Clinical Trials in Oncology
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy	NCT00006220	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	arsenic trioxid... tretinoin	15 Years -	Washington University School of Medicine
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma	NCT00036946	Lymphoma Unspecified Adu...	ziv-aflibercept	25 Years - 120 Years	Regeneron Pharmaceuticals
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00053027	Lymphoma	rituximab cladribine	18 Years -	Alliance for Clinical Trials in Oncology
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma	NCT00045266	Lymphoma Unspecified Adu...	ziv-aflibercept	25 Years - 120 Years	Regeneron Pharmaceuticals
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma	NCT00053092	Lymphoma	rituximab cyclophosphamid... fludarabine pho...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma	NCT00720447	Lymphoma	alemtuzumab donor lymphocyt... carmustine cytarabine etoposide melphalan allogeneic bone... peripheral bloo...	18 Years -	National Cancer Institute (NCI)
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00083213	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT00725062	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	CD4+CD25+ regul... allogeneic hema...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT00003311	Lymphoma	filgrastim cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... methotrexate vincristine sul...	16 Years -	M.D. Anderson Cancer Center
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma	NCT00004231	Lymphoma	aldesleukin filgrastim recombinant int... busulfan cyclophosphamid... cytarabine doxorubicin hyd... leucovorin calc... methotrexate prednisone teniposide vincristine sul... allogeneic bone... autologous bone... peripheral bloo...	18 Years -	Northwestern University
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma	NCT00101101	Lymphoma	Cyclophosphamid... Doxorubicin Vincristine Prednisone Dexamethasone Autologous Tumo... IL-2	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant	NCT02797470	HIV Infection Mature T-Cell a... Plasmablastic L... Recurrent Adult... Recurrent Adult... Recurrent Burki... Recurrent Folli... Stage III Folli... Stage III Mantl... Stage IV Follic... Stage IV Mantle...	Autologous Hema... Carmustine Cytarabine Etoposide Laboratory Biom... Lentivirus Vect... Melphalan Peripheral Bloo...	18 Years -	AIDS Malignancy Consortium
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer	NCT00005993	Breast Cancer Lymphoma	aldesleukin filgrastim recombinant hum... peripheral bloo...	18 Years - 65 Years	Masonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT00725062	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	CD4+CD25+ regul... allogeneic hema...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma	NCT00028665	Lymphoma	filgrastim rituximab carmustine cisplatin cyclophosphamid... etoposide bone marrow abl... peripheral bloo... radiation thera...	12 Years - 65 Years	Case Comprehensive Cancer Center
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma	NCT01412879	Lymphoma	rituximab bendamustine hy... cyclophosphamid... cytarabine dexamethasone doxorubicin hyd... leucovorin calc... methotrexate vincristine sul...	18 Years - 65 Years	SWOG Cancer Research Network
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma	NCT00443976	Non-Hodgkins Ly... Unspecified Adu...	Aurora kinase i...	18 Years -	Canadian Cancer Trials Group

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: